Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

被引：0
|
作者：
Berenson, James R.
Yellin, Ori
Bessudo, Alberto [1 ]
Boccia, Ralph V. [2 ]
Noga, Stephen J. [3 ]
Gravenor, Donald S. [4 ]
Patel-Donnelly, Dipti [5 ]
Siegel, Robert S. [6 ]
Kewalramani, Tarun [7 ]
Gorak, Edward J. [8 ]
Swift, Regina A. [9 ]
Mayo, Debra [10 ]
机构：
[1] San Diego Pacific Oncol Hematol Associates Inc, Encinitas, CA USA
[2] Ctr Canc & Blood Disorders, Bethesda, MD USA
[3] Weinberg Canc Inst Franklin Sq, Sect Hematol, Baltimore, MD USA
[4] Family Canc Ctr, Memphis, TN USA
[5] Virginia Canc Specialists PC, Fairfax, VA USA
[6] George Washington Univ, Med Ctr, Washington, DC 20037 USA
[7] Lahey Clin Med Ctr, Burlington, MA 01803 USA
[8] Geisinger Med Ctr, Danville, PA 17822 USA
[9] James R Berenson MD Inc, Los Angeles, CA USA
[10] Cephalon Inc, Frazer, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：808 / 809
页数：2
相关论文
共 50 条
  • [31] Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program
    Siegel, David S.
    Jagannath, Sundar
    Hajek, Roman
    Dimopoulos, Meletios A.
    Yoon, Sung-Soo
    Lonial, Sagar
    Laubach, Jacob P.
    Graef, Thorsten
    Pietrangelo, Dina
    Lupinacci, Lisa
    Reiser, David
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 813 - 814
  • [32] Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
    Cerchione, Claudio
    Nappi, Davide
    Di Perna, Maria
    Zacheo, Irene
    Pareto, Anna Emanuele
    Picardi, Marco
    Catalano, Lucio
    Pane, Fabrizio
    CASE REPORTS IN HEMATOLOGY, 2016, 2016
  • [33] PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB
    Mian, M.
    Pescosta, N.
    Luminari, S.
    Badiali, S.
    Marcheselli, L.
    Patriarca, F.
    Zambello, R.
    Mondello, P.
    Pascarella, A.
    Pitini, V.
    Cortelazzo, S.
    HAEMATOLOGICA, 2014, 99 : 637 - 637
  • [34] Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib
    Mian, Michael
    Pescosta, Norbert
    Badiali, Stefania
    Cappelletto, Paola Cristina
    Marcheselli, Luigi
    Luminari, Stefano
    Patriarca, Francesca
    Zambello, Renato
    Pascarella, Anna
    Tagariello, Giuseppe
    Marabese, Alessandra
    Mondello, Patrizia
    Billio, Atto
    Cortelazzo, Sergio
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 944 - 947
  • [35] PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB
    Mian, M.
    Pescosta, N.
    Luminari, S.
    Badiali, S.
    Marcheselli, L.
    Patriarca, F.
    Zambello, R.
    Mondello, P.
    Pascarella, A.
    Marabese, A.
    Pitini, V.
    Cortelazzo, S.
    HAEMATOLOGICA, 2014, 99 : 382 - 383
  • [36] A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
    Berenson, James R.
    Hilger, James D.
    Yellin, Ori
    Boccia, Ralph V.
    Matous, Jeffrey
    Dressler, Kenneth
    Ghazal, Hassan H.
    Jamshed, Saad
    Kingsley, Edwin C.
    Harb, Wael A.
    Noga, Stephen J.
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    ANNALS OF HEMATOLOGY, 2014, 93 (01) : 89 - 98
  • [37] A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
    James R. Berenson
    James D. Hilger
    Ori Yellin
    Ralph V. Boccia
    Jeffrey Matous
    Kenneth Dressler
    Hassan H. Ghazal
    Saad Jamshed
    Edwin C. Kingsley
    Wael A. Harb
    Stephen J. Noga
    Youram Nassir
    Regina A. Swift
    Robert Vescio
    Annals of Hematology, 2014, 93 : 89 - 98
  • [38] A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma
    Popat, Rakesh
    Plesner, Torben
    Davies, Faith
    Cook, Gordon
    Cook, Mark
    Elliott, Peter
    Jacobson, Eric
    Gumbleton, Todd
    Oakervee, Heather
    Cavenagh, Jamie
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (05) : 714 - 717
  • [39] Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study
    Offidani, Massimo
    Maracci, Laura
    Corvatta, Laura
    Marina, Liberati Anna
    Ballanti, Stelvio
    Attolico, Imma
    Caraffa, Patrizia
    Alesiani, Francesco
    di Toritto, Tommaso Caravita
    Gentili, Silvia
    Tosi, Patrizia
    Brunori, Marino
    Derudas, Daniele
    Ledda, Antonio
    Gozzetti, Alessandro
    Cellini, Claudia
    Malerba, Lara
    Mele, Anna
    Felici, Stefano
    Galimberti, Sara
    Mondello, Patrizia
    Pulini, Stefano
    Coppetelli, Ugo
    Fraticelli, Paolo
    Rizzi, Rita
    Leoni, Pietro
    BLOOD, 2014, 124 (21)
  • [40] A Phase 1 Study of Everolimus and Bendamustine in Patients with Relapsed or Refractory Lymphoid Malignancies and Myeloma
    Davis, Julian R.
    Jonas, Brian A.
    Tuscano, Joseph M.
    Rosenberg, Aaron Seth
    Abedi, Mehrdad
    BLOOD, 2017, 130
12345